When Betty-Lynn LaFrance was diagnosed with lung cancer in 2017, she was completely shocked as she’d never smoked and had been very active her entire life. Born and raised in Pembroke, Ont., where she still lives with her husband of 34 years, LaFrance has three children and seven grandchildren. When she was diagnosed with ALK+ non-small cell lung […]
In its 2019 budget on Tuesday, the federal government confirmed it will work with partners to move forward on three foundational elements of national pharmacare. The initial steps are the creation of a new national drug agency and a national formulary, which were both recommended by the advisory council on the implementation of national pharmacare in its interim […]
The Competition Bureau has discontinued an inquiry into allegations that Janssen Inc. inhibited the Canadian market for biosimilar products that compete with its biologic product Remicade. Given the significant impact of biologics in Canada, the report highlights some of the competition issues related to the biologics and biosimilars market. Although the bureau expressed concerns about the […]
Reformulary Group has signed an agreement with the Great-West Life Assurance Co. to make its managed formulary available to the insurer’s plan sponsors. The formulary was curated with the expert advice of an independent panel of doctors and pharmacists, which reviews research and evidence about drugs. Read: Reformulary Group launches early warning system for high-cost drugs “The […]
As a job title, ‘drug case manager’ can imply different things across the health-care and benefits industries. In Canada, a drug case manager may be part of a drug manufacturer’s patient support program or an insurance company’s preferred pharmacy network, while hospitals have case managers at various levels, says Suzanne Nagy, drug consulting leader for […]
While the Canadian Life and Health Insurance Association is in agreement with the general intent of the Ontario government’s proposed changes to the OHIP+ program, it’s strongly encouraging a number of considerations to preserve the revised program as planned and avoid unintended consequences. The proposed amendments would roll back the OHIP+ program, which was introduced […]
As the federal government continues its consultations on a national pharmacare system, many questions are still up in the air. Will the new system follow a single-payer model? And if so, what would be the implications for a private-payer system? As discussions examine the various possibilities, the private industry says pharmacare reform is a complex issue that requires more […]
Something interesting happened this month as we examined the 2018 experience of two different plan sponsors in two separate geographies with different demographics. The only similarity between the plans is they both have 80,000 or more individual claimants on their drug plan annually. At the same time last year, we completed a series of predictive analytics on […]
Treating mental health with medications is very different from treating an infection, so why do many people, and many employers, treat them like they’re one and the same? When enhancing communications around wellness programs, plan sponsors should seek innovative ways to support employees with how they use medications and help them understand the interactions between drugs and mental […]
A majority of Canadians, health-care providers, labour organizations and employers agree a national single-payer system is an idea whose time has come, according to a report by the Broadbent Institute. Canada has attempted to bring in a national pharmacare plan nine times in the last 73 years — in 1945, 1947, 1962, 1964, 1966, 1970, 1997, 2002, and […]